Alchemy - Issue 28 - Page 17

Learn more about the HMST Laboratory: platforms.monash.edu/hmstlab/ and the HMSTrust and grant: hmstrust.org.au/casestudies/monash-institute-pharmaceuticalsciences-mips From left to right: HMSTrust Lab Senior Administrative Officer Nicole McMillan with Victorian Minister for Health Jill Hennessy, Monash President and Vice Chancellor Professor Margaret Gardner AO and Associate Professor Michelle McIntosh. DEVELOPING A SIMPLE SOLUTION TO A GLOBAL HEALTH PROBLEM Each year, nearly 300,000 women globally die from pregnancy-related causes, with postpartum haemorrhage (PPH – excessive bleeding after childbirth) the leading contributor to these deaths. Although PPH can be effectively prevented or treated with an injection of oxytocin, access to the drug is limited as it requires refrigerated storage to maintain efficacy and trained medical personnel to administer. The Inhaled Oxytocin Project seeks to develop a novel aerosol delivery system for oxytocin that can be administered with a simple, low-cost, disposable device immediately after childbirth. This will increase access to this life-saving medication in resource-poor settings – where a large number of women give birth outside medical facilities or in understaffed and underresourced clinics. The project has now reached the exciting clinical trial phase. The capabilities of the new HMSTrust Laboratory will support this translational research being undertaken at MIPS. The Inhaled Oxytocin Project was recently included in the Innovation Countdown 2030 report, Reimagining Global Health: 30 highimpact innovations to save lives. See page 6 15